Inclusion Criteria:

   - Histologically confirmed diagnosis of a primary malignant glioma.

   - Symptomatic peritumoral brain edema requiring initiation or increase of dexamethasone
   treatment.

   - If a patient is on dexamethasone for treatment of symptomatic peritumoral brain edema,
   the dose must be stable and should not exceed 24mg/dl for a minimum of 7 days prior to
   Baseline.

   - Presence of peritumoral brain edema confirmed by MRI scan or comparable diagnostic
   technology obtained within 21 days of Baseline.

   - Capable of self-administration of subcutaneous injections twice daily for 8 weeks or
   availability of assistance from caregiver.

Exclusion Criteria:

   - Need for surgery, radiosurgery or radiation therapy or the introduction of new
   chemotherapeutic regime within 2 weeks of study treatment.

   - Systemic steroid use for any other indication than peritumoral brain edema.

   - Patients on dexamethasone or anticonvulsant therapy.

   - Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine
   metabolic disease which could put the patient at unusual risk for study participation.

   - Central nervous system (CNS) infection.

   - Conditions that are considered contradictions for patients to receive niacin